NCT03343834View on ClinicalTrials.gov

Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation

NACompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

December 21, 2017

Primary Completion Date

August 5, 2021

Study Completion Date

August 5, 2021

Conditions
Epstein-Barr ViraemiaHematologic DiseasesAllogeneic Disease
Interventions
BIOLOGICAL

biological collection

"At D0:~* blood samples~* saliva sample~At D8: blood sample~the results will be compared to the analysis of EBV transcripts that are specific for the latent or replicative phase of the virus by reverse transcription-quantitative PCR (RT-qPCR), and to the detection of free virus in the saliva, which is associated with viral reactivation"

Trial Locations (1)

75012

Service d'hématologie Clinique, Paris

All Listed Sponsors
collaborator

Institut National de la Santé Et de la Recherche Médicale, France

OTHER_GOV

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03343834 - Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter